Yeah, never did get those extra NGIO dividends. His

New Post Public Reply Private Reply Replies (2) Message Board
tc2000chartreader All Aboard #20915
444
Yeah, never did get those extra NGIO dividends. His ‘explanation’ was the difference between a public company like GNBT, and non public like ngio. So between the record date and pay date, the public traded company carries the due bill process and the non public does not. I would be fine with that had not every single PR by the company leading up to the pay date stating the same 2 for 5 dividend. It was only after the fact that they said NGIO was different since it was non public company.

“ FINRA has determined that the original August 30 record date is too long ago to adequately track all the pay due bills from stock being bought and sold by investors, so a new record date of February 17th, 2020 has been established. This will insure everyone who has bought stock since August and retains the stock will receive the dividend not by way of a Pay Due Bill, but rather, directly from Generex. Those who sold stock after the original record date need not worry about anything as they were formally entitled to receive the dividend, but they would have had to transfer the dividend to the buyer of their shares. With the new February 17th record date being established, those who are entitled to receive the 5/2 stock dividend in Generex and the 5/2 stock dividend in NuGenerex Immuno-Oncology will receive it directly from the company.
th
In addition, the pay date is now February 24th and ex-date is February 25 . If a
shareholder sells the stock after the record date the pay due bill process will be in full effect and the shareholder will be required to transfer the dividend stock to the buyer. The ex-date rule in this situation is found in FINRA Rules Section 11140 (b)(2), which reads as follows: “(2) In respect to cash dividends or distributions, stock dividends and/or splits, and the distribution of warrants, which are 25% or greater of the value of the subject security, the ex-dividend date shall be the first business day following the payable date.””

Then he tried to tell me it was the same with the prior NGIO dividend. When you have a non public company, the record date is the date you use since it is not traded so there would be no trading between the record and pay dates. I did not purchase GNBT during the record and pay dates to know if those that did got NGIO. I thought I read that they did, however I have no proof.

That being said, I believe now that we may not be entitled to those NGIO shares. Not because of the dates but rather because the dividend was less than 25% of the company each time. Only on special dividends of 25% or more do you have the due bill process. So the 2 ngio for 5 GNBT since only amounted to less than 5-6% of NGIO being distributed. GNBT holds more than 90% of NGIO. So the reason given was not correct, in my opinion, however the end result may be correct since it was less than 25%.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mazu Culture Forum Unveils New Initiatives in China

Updated Category News Views 126

A Cultural Tapestry Unfurls in Putian Picture this: a kaleidoscope of cultures and ideas unraveling in the coastal city of Putian. The 11th Global Mazu Culture Forum kicks off on October 31, bringing together minds—both fresh and seasoned—from an impressive array of 47 countries and regions. It's more than a forum; it's a vibrant crossroads of innovation, tradition,...

Continue Reading
Foxconn Spotlights AI Advancements at Tech Day 2026

Updated Category News Views 127

Foxconn's Bold Step into AI Infrastructure Foxconn, the tech giant that most folks recognize for its sheer prowess in electronics manufacturing, isn't just idling on past laurels. During the 7th annual Hon Hai Tech Day 2026, it was a showcase of fireworks that left attendees buzzing about the future of AI infrastructure and beyond. And when Foxconn says it's transforming,...

Continue Reading
Haunted Attraction Insights from the Queen of Haunts

Updated Category News Views 5

Admit it—everyone's got that one fear that sends shivers down their spine. Whether it's the slithering scales of a snake or the manic laughter of a clown, those phobias are what make haunted attractions such a hit for thrillseekers across the country. Amber Arnett-Bequeaith, the so-called Queen of Haunts, knows a thing or two about turning those fears into unforgettable...

Continue Reading
European Doctors Explore Chinese Aesthetic Innovations

Updated Category News Views 39

Pioneering Exchange in Regenerative Aesthetics Ever seen European doctors flocking to China to learn about beauty techniques? That's the scene as aphranel®, the brainchild of MOYOM Biotech, ushers in a week-long clinical exchange under 'The Norns' Weave.' The whole deal aims to unravel how Chinese practices could shape Europe's aesthetic landscape. Yep, it's all about...

Continue Reading
Gooru AI Unveils Platform to Scale Human Expertise

Updated Category News Views 67

A New Wave of AI-Powered Solutions Hot off the press, Gooru AI's recent shindig in the heart of Dallas aimed to showcase something they call 'Digital Goorus.' Now that might sound like a newage tech gimmick but peel back the layers and you find an ambitious attempt to let folks spread their smarts without having to be everywhere all at once. Imagine being able to crack...

Continue Reading
Nanoscope Therapeutics Aims for Eye-Catching Advances

Updated Category News Views 69

Gearing Up for a Boston Showcase Nanoscope's High-Stakes Boston Rendezvous In a move set to grab some serious eyeballs, Nanoscope Therapeutics is geared up to strut their stuff at Advanced Therapies USA 2026 in Boston. Scheduled for November 4–5 at the Hynes Convention Center, the event isn't just another pitstop—it's a billboard for what these guys have cooking. With...

Continue Reading
Okta Joins S&P 500 Amidst Major Index Shuffles

Updated Category News Views 172

Okta Leaps to S&P 500: A Power Play You blink for a second, and boom, Okta's sitting at the big kids' table—the S&P 500. You know how rare that move is? It’s like snagging an invite to the party everyone wants to attend. Swapping out Kenvue Inc. (NYSE: KVUE), which Kimberly-Clark (NASD: KMB) is scooping up, Okta's maneuver signifies a hefty endorsement of its growth...

Continue Reading
MediaGo Wins Big in France with Optimized Strategies

Updated Category News Views 75

MediaGo's Winning Edge in Advertising Shake the dust off your boots and get ready for a tale of triumph straight out of San Francisco. MediaGo, the top dog in global intelligent advertising platforms, just added a couple of shiny awards to its trophy case thanks to the prestigious Les Cas d'OR 2026 in France. And let me tell ya, these wins aren't just about some pretty...

Continue Reading
Lecanemab's New Data: What Investors Should Monitor

Updated Category News Views 71

Lecanemab: A Bold Step in Alzheimer's Treatment? Investors eyeing the biotech sector should pay close attention to the upcoming CTAD conference in 2026, where BioArctic AB's partner, Eisai, is set to present fresh data on lecanemab (Leqembi®). This isn't just another pharma front-page story—this is about potential breakthroughs in Alzheimer's treatment that's caught...

Continue Reading
Fintech Shake-Up: OPay's $4B NYSE IPO Arrival

Updated Category News Views 33

It's a big day on Wall Street as OPay dives into the NYSE with a hefty market cap of over $4 billion, signaling a major moment for the fintech arena. Oh, how times are shifting! Today marks the debut of OPay under the ticker 'OPAY,' and let me tell you, there's a buzz in the air that could quicken any seasoned trader's pulse. OPay's Big Day: A New Era of Fintech Their...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Consumer Product Risks: Insights from Legal Experts

Updated Category News Views 131

Investigation into Defective Consumer Products The Law Offices of Jason Turchin is currently investigating various claims related to defective consumer products that can potentially harm individuals. These products include commonly used items such as space heaters and HVAC systems, as well as kitchen equipment like coffee makers and pressure cookers. Each of these items...

Continue Reading
Nauticos Takes Bold Steps Toward Uncovering Earhart's Mystery

Updated Category News Views 303

Nauticos Aims to Solve a Historic Mystery Nauticos, a leader in deep-sea exploration and historical research, has announced an exciting new expedition to locate Amelia Earhart's Lockheed Electra. This groundbreaking mission is fueled by proprietary data that pinpoints the likely resting place of the iconic aircraft. The research advances our understanding of where Earhart...

Continue Reading
Equitable Bank Achieves Historic $300 Million Deposit Note Success

Updated Category News Views 197

Equitable Bank Closes Impressive $300 Million Deposit Note Issuance Equitable Bank, Canada's Challenger Bank™, has successfully closed a monumental $300 million floating rate deposit note issuance. This remarkable achievement marks the tightest spread on record for deposit notes of a similar term issued by the bank. The overwhelming response from investors demonstrates...

Continue Reading
Exploring the Long-Term Gains of Sprouts Farmers Market Stock

Updated Category News Views 98

Understanding the Growth of Sprouts Farmers Market Stock Over the last decade, Sprouts Farmers Market (NASDAQ: SFM) has demonstrated remarkable growth, consistently surpassing market returns by an impressive 3.05% annually. With average annual returns reaching 14.93%, this company's performance is a topic of great interest among investors. Initial Investment Insights...

Continue Reading
Anticipating Royalty Pharma's First Quarter 2025 Financial Results

Updated Category News Views 119

Upcoming Financial Results Announcement Royalty Pharma plc (Nasdaq: RPRX) is gearing up to share its financial journey for the first quarter of 2025 on May 8, 2025. As one of the largest buyers of biopharmaceutical royalties, the firm is set to unveil its latest financial results early in the day, prior to the opening of U.S. markets. This announcement will give investors...

Continue Reading